Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jns.2018.04.028 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Nivolumab-Induced Neuromyopathy: A Case Report.
Cureus
September 2024
Nephrology, Staten Island University Hospital, Staten Island, USA.
Nivolumab is an immune checkpoint inhibitor (ICI) that treats various malignancies. Although ICIs have proven efficacious, they can also have detrimental side effects. We present a case of nivolumab-induced quadriparesis mimicking Guillain-Barré syndrome in a patient with stage III squamous cell carcinoma (SCC) of the pharynx with a chronic tracheostomy, who presented after being found unconscious at home.
View Article and Find Full Text PDFNivolumab-Induced Cytokine Release Syndrome: A Case Report and Literature Review.
Am J Case Rep
April 2024
Intensive Care Unit, UCL Namur University Hospital, Yvoir, Belgium.
BACKGROUND CRS (cytokine release syndrome) is a massive activation of the inflammatory system characterized by a supra-physiological rate of inflammatory cytokines. The interleukin 6 cytokine plays a central role in CRS. The main clinical sign of CRS is fever, but CRS can lead to multiple organ failure in severe cases.
View Article and Find Full Text PDFNivolumab-Induced Colitis in a Patient With Esophageal Adenocarcinoma: A Case Report.
Cureus
July 2023
Department of Pathology, Aretaieion University Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, GRC.
Nivolumab is an immune checkpoint inhibitor used in the treatment of several types of cancer. Among the adverse effects of this drug, immune-mediated colitis (IMC) has been described. However, in contrast to other checkpoint inhibitors, such as ipilimumab, drug-induced colitis due to nivolumab is not commonly reported.
View Article and Find Full Text PDFArticle Synopsis
- Baseline assessment and regular monitoring using patient history, clinical exams, lab tests, and noninvasive imaging can help detect side effects from immune checkpoint inhibitors early.
- The text highlights various cardiotoxic effects linked to immune checkpoint inhibitors, including conditions like pericarditis and myocarditis.
- A case study is presented of a middle-aged man with advanced esophageal cancer who experienced acute heart failure due to nivolumab-induced cardiotoxicity, despite having no prior heart issues or significant risk factors.
Nivolumab-induced acute tubular injury: A case report.
Clin Case Rep
March 2023
Department of Nephrology Chang Gung Memorial Hospital, Linkou Taiwan.
Nivolumab belongs to immune checkpoint inhibitors (ICIs). ICIs-induced kidney injury is rare and acute interstitial nephritis (AIN) is the majority. A 58-year-old woman had gastric cancer treated with nivolumab.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!